推荐产品
方案
≥98% (TLC)
mp
≥300 °C (lit.)
SMILES字符串
NC(Cc1ccc(O)cc1)C(O)=O
InChI
1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)
InChI key
OUYCCCASQSFEME-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
生化/生理作用
多巴胺和其他儿茶酚胺的氨基酸前体
替代产品
产品编号
说明
价格
法规信息
新产品
Blood, 125(11), 1759-1767 (2015-02-04)
Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a recently described subtype of T-ALL characterized by a unique immunophenotype and genomic profile, as well as a high rate of induction failure. Frequent mutations in cytokine receptor and Janus kinase
Experimental neurology, 270, 29-40 (2014-12-30)
Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist. The clinical disease can be difficult to treat effectively. MuSK autoantibodies affect the neuromuscular junction in several
European heart journal, 36(12), 743-750 (2014-05-20)
There is now compelling evidence that cells committed to a cardiac lineage are most effective for improving the function of infarcted hearts. This has been confirmed by our pre-clinical studies entailing transplantation of human embryonic stem cell (hESC)-derived cardiac progenitors
The New England journal of medicine, 372(7), 621-630 (2015-02-12)
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with
Leukemia, 29(8), 1763-1770 (2015-03-13)
FIP1L1-PDGFRA is a constitutively activated kinase described in chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). Imatinib is clinically active in FIP1L1-PDGFRA-positive diseases. Using in vitro screening to identify imatinib-resistant mutations, we frequently detected a Phe to Ser exchange at
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门